Eli Lilly snaps six straight sessions of losses
Eli Lilly (NYSE:LLY) shares were on track to snap six straight sessions of losses on Thursday, as the stock rose 1.9% at $790 ...
Yahoo Finance10d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Company leaders also said that versions of tirzepatide, the active ingredient behind Mounjaro and Zepbound, made by ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.
Even a juggernaut like Eli Lilly (NYSE: LLY) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat, ...
Yahoo Finance11d
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio ...
Investopedia on MSN10d
Eli Lilly Stock Tumbles as Q3 Sales, Profits Fall Well Short of Estimates
Eli Lilly shares sank 10% Wednesday morning after its third-quarter results came in well below what analysts were expecting.
Wall Street Journal10d
Eli Lilly’s Bad Quarter Doesn’t Change Long-Term Math on Obesity Bonanza
Sales of GLP-1 drugs Mounjaro and Zepbound disappointed investors. (Shelby Knowles/Bloomberg News) Eli Lilly had a bad ...
The Associated Press - Business News on MSN10d
Stock market today: Nasdaq edges back from its record as chip companies and Eli Lilly slump
U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company.
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Nasdaq10d
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
INDIANAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024. "Lilly had another strong growth quarter in Q3 ...